When a Children's Medical Guideline Fails the Safeguard Test

An audit of Australia's paediatric gender guideline raises serious questions about evidence, informed consent and diagnostic safeguards.

---

When we treat children in medicine, we apply more care, not less. The younger and more vulnerable the patient, the higher the duty to get the basics right: current evidence, full disclosure of risks, and clear processes for who decides what. This is not contentious. It is how Australian medicine is meant to work, and it is what parents, regulators and the courts assume when they trust a paediatric clinical standard.

So when a guideline governing irreversible medical interventions in children appears to fail ordinary safeguard tests, that is a matter the public is entitled to know about.

Active Watchful Waiting Inc. has audited the Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, Version 1.4 — published in November 2023 by the Royal Children's Hospital Melbourne and endorsed by the Australian Professional Association for Trans Health (AusPATH). The audit applies ordinary Australian regulatory frameworks: the National Health and Medical Research Council's standards for clinical guidelines, the Commission on Safety and Quality in Health Care's informed consent framework, the AHPRA Code of Conduct, and the High Court's settled standard for material-risk disclosure in Rogers v Whitaker (1992). Three findings emerged. Each one stands on its own. Each can be verified in minutes by reading the document itself.

A reference list that stops in 2017

The first finding is the simplest. The guideline has seventy references. Every one of them is dated 2017 or earlier. There are no references from 2018, 2019, 2020, 2021, 2022 or 2023 — not in the original document, and not added in the Version 1.4 update. Anyone can check this: pages 31 and 32 list every reference.

What happened in the missing six years was not minor. The Cass Review interim report appeared in 2022. The UK's NICE issued evidence reviews on puberty blockers and gender-affirming hormones in 2021. Sweden's Karolinska Institute and Finland's COHERE national authority both revised their guidance. The Tavistock children's gender service in London was reviewed and announced for closure. None of this is footnoted, cited or addressed in the Australian standard for paediatric care. The 2023 update added a substantial new section on GP-led prescribing — but added not a single 2018–2023 reference. The omission is documentary. Whether oversight or selection, it is a problem against the NHMRC's Standard 6 (evidence base) and Standard 9 (currency and updating) for clinical practice guidelines.

"Informed consent has been obtained"

The second finding concerns informed consent. The guideline's only consent requirement is that "informed consent has been obtained" (pages 23 and 24). There is no consent form template. There is no minimum list of disclosures that must be made before consent can be considered valid. There is no process for verifying that the young person and their family actually understand what they are consenting to.

The document acknowledges, in its own body text, that the long-term impact of puberty suppression on bone mineralisation is "unknown" (p. 15), that the effect of testosterone on reproductive potential when taken in adolescence is "unknown" (p. 13), and that there is "no empirical evidence" for the appropriate age to introduce hormones (p. 16). None of these acknowledgments is converted into a required disclosure in the consent process. They appear in the document, but the document does not require they appear in the conversation.

What Rogers v Whitaker actually decided

To see why this matters, the relevant case is Rogers v Whitaker — a 1992 High Court decision that still defines what informed consent means in Australian law.

In the late 1980s, a woman named Marlene Whitaker had eye surgery to improve vision in her right eye. Her surgeon, Dr Rogers, did not warn her of a rare complication: that operating on one eye could trigger a condition called sympathetic ophthalmia, causing blindness in both eyes — including the healthy left eye that was not being operated on. The risk was approximately one in fourteen thousand. It happened. She lost almost all her sight.

The High Court ruled the surgeon negligent — and in doing so, set the modern Australian standard for informed consent. The court rejected the older idea that doctors only had to tell patients what other doctors would normally tell them. Instead, it established a patient-centred test: a risk is "material," and must be disclosed, if a reasonable person in the patient's position would be likely to attach significance to it, or if the doctor knows this particular patient would.

It is not about how rare the risk is. It is about whether a person making the decision would want to know.

That is the standard a parent considering puberty blockers or cross-sex hormones for their child is owed — and the standard a young person is owed where they are competent to consent. The guideline acknowledges, in its own pages, that bone effects are unknown, that fertility effects are unknown, that the right age to begin hormones is unknown. A reasonable parent in those circumstances would attach significance to that. The guideline does not require the clinician to say it.

Mandatory or discretionary?

The third finding is an internal inconsistency. The guideline specifies, as a mandatory criterion for both puberty suppression and gender-affirming hormones, a diagnosis of Gender Dysphoria in Adolescence made by a mental health clinician with expertise in child and adolescent development and psychopathology (pages 23 and 24, criterion 1).

The Version 1.4 update — the new GP section — describes a primary-care-led prescribing pathway in which mental health referral is treated as discretionary. GPs "should discuss this with patients and offer referrals to psychologists, psychiatrists, or other mental health professionals if and as required" (page 21). The document does not state which passage governs. A GP relying on the new section may believe themselves to be in compliance with the guideline while not satisfying the guideline's own mandatory criterion.

Australia's legal framework for paediatric gender medicine — set out in Re Kelvin (2017) and Re Imogen (2020) — assumes that the clinical assessment underpinning treatment has been conducted to a specified standard. The Family Court in Re Kelvin declined to require court authorisation for stage 2 hormone treatment in undisputed cases on the basis that the prevailing Australian clinical guidelines provided adequate safeguards. Where the guideline itself is internally inconsistent about whether mental health diagnosis is mandatory or discretionary, that presumption is exposed. Assessment is a safeguard. It is not an obstacle to care; it is the process that makes care safe.

The test is not ideology

None of this requires anyone to hold a position on the contested clinical questions around gender-affirming care for minors. It does not require trust in one camp or another. The audit asks a narrower and more answerable question: does the document meet ordinary Australian standards for clinical guidelines? Does it engage with current evidence? Does it specify a consent process? Is it internally consistent?

The more vulnerable the child, the stronger the safeguards should be. Yet Australia's paediatric gender guideline appears weakest precisely where safeguards matter most — current evidence, informed consent and clear diagnostic assessment. That is not an ideological objection. It is a regulatory one. And it is verifiable in minutes by anyone willing to read the document.

Catherine Anderson-Karena

Link to audit: Oracle test of Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents, Version 1.4